Literature DB >> 17522429

Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.

Michael L Volk1, Jose C Hernandez, Grace L Su, Anna S Lok, Jorge A Marrero.   

Abstract

Current surveillance strategies for hepatocellular carcinoma (HCC) are applied uniformly in patients with cirrhosis, regardless of their cancer risk. The aim of this study was to compare the performance characteristics of the biomarkers alpha-fetoprotein (AFP), des-gamma carboxyprothrombin (DCP), and lectin-bound AFP (AFP-L3) in the diagnosis of HCC, and to determine the effect of risk factors for HCC on test performance. Eighty-four patients with HCC and 169 patients with cirrhosis were enrolled and their serum analyzed for total AFP, AFP-L3 and DCP. Receiver-operating characteristic (ROC) curves were constructed to determine the performance characteristics. DCP was significantly better than total AFP or AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. When subjects were divided into two groups by their risk for HCC, all 3 markers had a lower sensitivity and area under the ROC curve in the high-risk group compared to the low-risk group. In conclusion, DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Serum biomarkers may be less sensitive and specific in the highest risk patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522429     DOI: 10.3233/cbm-2007-3202

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  55 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.

Authors:  Peter Richardson; Zhigang Duan; Jennifer Kramer; Jessica A Davila; Gia L Tyson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-07       Impact factor: 11.382

3.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

Review 4.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

5.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

6.  Early detection of hepatocellular carcinoma through surveillance using biomarkers.

Authors:  Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-02

7.  Updates in the management of hepatocellular carcinoma.

Authors:  Robert Wong; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

8.  Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

Review 9.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

10.  Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China.

Authors:  Peipei Song; Xiaobin Feng; Keming Zhang; Tianqiang Song; Kuansheng Ma; Norihiro Kokudo; Jiahong Dong; Wei Tang
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.